APA (7th ed.) Citation

B, C., A, K., Y, T., D, v. d. H., JA, S., HSB, B., . . . P, N. (2021). Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial. Annals of the rheumatic diseases, 80(7), 848. https://doi.org/10.1136/annrheumdis-2020-219214

Chicago Style (17th ed.) Citation

B, Combe, et al. "Filgotinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Phase III Randomised Clinical Trial." Annals of the Rheumatic Diseases 80, no. 7 (2021): 848. https://doi.org/10.1136/annrheumdis-2020-219214.

MLA (9th ed.) Citation

B, Combe, et al. "Filgotinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Phase III Randomised Clinical Trial." Annals of the Rheumatic Diseases, vol. 80, no. 7, 2021, p. 848, https://doi.org/10.1136/annrheumdis-2020-219214.